487 related articles for article (PubMed ID: 17351764)
21. Proprotein convertases subtilisin/kexin type 9, an enzyme turned escort protein: hepatic and extra hepatic functions.
Mbikay M; Mayne J; Chrétien M
J Diabetes; 2013 Dec; 5(4):391-405. PubMed ID: 23714205
[TBL] [Abstract][Full Text] [Related]
22. Proprotein convertase subtilisin/kexin 9 inhibitors: an emerging lipid-lowering therapy?
Dragan S; Serban MC; Banach M
J Cardiovasc Pharmacol Ther; 2015 Mar; 20(2):157-68. PubMed ID: 24938457
[TBL] [Abstract][Full Text] [Related]
23. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.
Bergeron N; Phan BA; Ding Y; Fong A; Krauss RM
Circulation; 2015 Oct; 132(17):1648-66. PubMed ID: 26503748
[TBL] [Abstract][Full Text] [Related]
24. Comparative study of the binding pockets of mammalian proprotein convertases and its implications for the design of specific small molecule inhibitors.
Tian S; Jianhua W
Int J Biol Sci; 2010 Feb; 6(1):89-95. PubMed ID: 20151049
[TBL] [Abstract][Full Text] [Related]
25. On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effects.
Tavori H; Rashid S; Fazio S
Atherosclerosis; 2015 Feb; 238(2):264-70. PubMed ID: 25544176
[TBL] [Abstract][Full Text] [Related]
26. [Proprotein convertases - family of serine proteases with a broad spectrum of physiological functions].
Małuch I; Walewska A; Sikorska E; Prahl A
Postepy Biochem; 2016; 62(4):472-481. PubMed ID: 28132449
[TBL] [Abstract][Full Text] [Related]
27. The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications.
Benjannet S; Rhainds D; Hamelin J; Nassoury N; Seidah NG
J Biol Chem; 2006 Oct; 281(41):30561-72. PubMed ID: 16912035
[TBL] [Abstract][Full Text] [Related]
28. Biologics for the treatment of dyslipidemias: a look beyond conventional therapy.
Yoon CH; Watson K
Ann Pharmacother; 2014 Feb; 48(2):238-49. PubMed ID: 24259646
[TBL] [Abstract][Full Text] [Related]
29. Understanding PCSK9 and anti-PCSK9 therapies.
McKenney JM
J Clin Lipidol; 2015; 9(2):170-86. PubMed ID: 25911073
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of PCSK9 as a novel strategy for the treatment of hypercholesterolemia.
Lopez D
Drug News Perspect; 2008; 21(6):323-30. PubMed ID: 18836590
[TBL] [Abstract][Full Text] [Related]
31. Proprotein convertases: "master switches" in the regulation of tumor growth and progression.
Bassi DE; Fu J; Lopez de Cicco R; Klein-Szanto AJ
Mol Carcinog; 2005 Nov; 44(3):151-61. PubMed ID: 16167351
[TBL] [Abstract][Full Text] [Related]
32. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
Zaid A; Roubtsova A; Essalmani R; Marcinkiewicz J; Chamberland A; Hamelin J; Tremblay M; Jacques H; Jin W; Davignon J; Seidah NG; Prat A
Hepatology; 2008 Aug; 48(2):646-54. PubMed ID: 18666258
[TBL] [Abstract][Full Text] [Related]
33. Structure and function of eukaryotic proprotein processing enzymes of the subtilisin family of serine proteases.
Van de Ven WJ; Roebroek AJ; Van Duijnhoven HL
Crit Rev Oncog; 1993; 4(2):115-36. PubMed ID: 8420571
[TBL] [Abstract][Full Text] [Related]
34. Knock-out mouse models of proprotein convertases: unique functions or redundancy?
Creemers JW; Khatib AM
Front Biosci; 2008 May; 13():4960-71. PubMed ID: 18508561
[TBL] [Abstract][Full Text] [Related]
35. PCSK9: an enigmatic protease.
Lopez D
Biochim Biophys Acta; 2008 Apr; 1781(4):184-91. PubMed ID: 18280815
[TBL] [Abstract][Full Text] [Related]
36. PCSK9 inhibition in LDL cholesterol reduction: genetics and therapeutic implications of very low plasma lipoprotein levels.
Marais AD; Kim JB; Wasserman SM; Lambert G
Pharmacol Ther; 2015 Jan; 145():58-66. PubMed ID: 25046268
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of PCSK9: a novel approach for the treatment of dyslipidemia.
Stawowy P; Just IA; Kaschina E
Coron Artery Dis; 2014 Jun; 25(4):353-9. PubMed ID: 24667128
[TBL] [Abstract][Full Text] [Related]
38. PCSK9: A key factor modulating atherosclerosis.
Li S; Li JJ
J Atheroscler Thromb; 2015; 22(3):221-30. PubMed ID: 25410128
[TBL] [Abstract][Full Text] [Related]
39. An update on the clinical development of proprotein convertase subtilisin kexin 9 inhibitors, novel therapeutic agents for lowering low-density lipoprotein cholesterol.
Ling H; Burns TL; Hilleman DE
Cardiovasc Ther; 2014 Apr; 32(2):82-8. PubMed ID: 24354905
[TBL] [Abstract][Full Text] [Related]
40. [Proprotein convertase subtilisin/kexin type 9 (PCSK9) and inhibitors].
Avci A; Demir K; Altunkeser BB
Turk Kardiyol Dern Ars; 2014 Oct; 42 Suppl 2():56-67. PubMed ID: 25693363
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
